Climb Bio (NASDAQ:CLYM) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Climb Bio (NASDAQ:CLYM) had its target price upped by research analysts at Robert W. Baird from $21.00 to $25.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s price target points to a potential upside of 71.21% from the company’s current price.

Other equities analysts have also recently issued reports about the company. Guggenheim assumed coverage on Climb Bio in a report on Monday, June 8th. They issued a “buy” rating and a $35.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Climb Bio in a report on Friday, July 17th. Wall Street Zen upgraded Climb Bio from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. BTIG Research upped their price target on Climb Bio from $20.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Piper Sandler set a $40.00 price objective on Climb Bio and gave the stock an “overweight” rating in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Climb Bio currently has an average rating of “Buy” and an average target price of $25.62.

Climb Bio Price Performance

Shares of NASDAQ:CLYM traded down $0.45 on Thursday, reaching $14.60. The company’s stock had a trading volume of 4,372,141 shares, compared to its average volume of 983,717. The stock’s 50-day moving average is $13.95 and its two-hundred day moving average is $10.69. Climb Bio has a 52-week low of $1.54 and a 52-week high of $18.33. The stock has a market capitalization of $838.74 million, a P/E ratio of -17.51 and a beta of 0.09.

Climb Bio (NASDAQ:CLYM) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.03. Equities analysts forecast that Climb Bio will post -0.82 earnings per share for the current fiscal year.

Institutional Trading of Climb Bio

A number of large investors have recently added to or reduced their stakes in CLYM. AQR Capital Management LLC acquired a new stake in shares of Climb Bio during the 1st quarter valued at about $27,000. Virtu Financial LLC bought a new position in shares of Climb Bio during the 4th quarter worth about $43,000. Qube Research & Technologies Ltd acquired a new position in Climb Bio in the 2nd quarter valued at approximately $43,000. Blair William & Co. IL acquired a new stake in Climb Bio during the fourth quarter worth $44,000. Finally, Legal & General Group Plc acquired a new stake in shares of Climb Bio during the 2nd quarter valued at about $45,000. 69.76% of the stock is currently owned by institutional investors.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.